Thiotepa-busulfan-fludarabine-based conditioning as a promising approach prior to allogeneic hematopoietic stem cell transplantation in patients with blastic plasmacytoid dendritic cell neoplasm
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05749-1 ↗Kurz gefasst
Fallbericht in der Zeitschrift Annals of Hematology, 2024. Verfasst von Xianbo Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No. 366 Wutong Road, Hangzhou, China. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Vidarabine, Transplantation Conditioning, Dendritic Cells. Die Arbeit nennt 14 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive myeloid malignancy associated with a poor prognosis. Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) has emerged as a potential treatment strategy for BPDCN, standardized conditioning regimens remain lacking. In this manuscript, we present two cases of BPDCN that were treated with a thiotepa-busulfan-fludarabine (TBF)-based conditioning regimen prior to allo-HSCT. Both cases demonstrated complete remission post-transplantation, sustained donor chimerism, and remission maintenance, suggesting the potential efficacy of the TBF conditioning regimen for BPDCN transplantation. Given the small sample size in our study, we emphasize caution and advocate for larger studies to confirm the efficacy of TBF in the treatment of BPDCN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No. 366 Wutong Road, Hangzhou, China.
- Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, China.
- Department of Pathology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
- Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No. 366 Wutong Road, Hangzhou, China. jiej0503@zju.edu.cn.
- Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, China. jiej0503@zju.edu.cn.
- Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No. 366 Wutong Road, Hangzhou, China. tonghongyan@zju.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Huang, X., Wang, S., Xu, Y., Mei, C., Han, Q., Wu, X., Du, F., Ren, Y., Jin, J., Tong, H., & Qian, J. (2024). Thiotepa-busulfan-fludarabine-based conditioning as a promising approach prior to allogeneic hematopoietic stem cell transplantation in patients with blastic plasmacytoid dendritic cell neoplasm. Annals of Hematology. https://doi.org/10.1007/s00277-024-05749-1
Vancouver
Huang X, Wang S, Xu Y, Mei C, Han Q, Wu X, et al. Thiotepa-busulfan-fludarabine-based conditioning as a promising approach prior to allogeneic hematopoietic stem cell transplantation in patients with blastic plasmacytoid dendritic cell neoplasm. Annals of Hematology. 2024. doi:10.1007/s00277-024-05749-1
BibTeX
@article{Huang2024,
author = {Huang, Xianbo and Wang, Shasha and Xu, Yu and Mei, Chen and Han, Qingmei and Wu, Xianhui and Du, Fengwei and Ren, Yanling and Jin, Jie and Tong, Hongyan and Qian, Jiejing},
title = {Thiotepa-busulfan-fludarabine-based conditioning as a promising approach prior to allogeneic hematopoietic stem cell transplantation in patients with blastic plasmacytoid dendritic cell neoplasm},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05749-1}
}
EUVIMED